Key Points
- Director Mark Alvino sold 13,500 Abeona shares on January 21 at an average price of $5.23 for $70,605, reducing his stake by 21.69% to 48,752 shares (about $254,973).
- This follows a prior sale on November 13 when Alvino sold 15,000 shares at $4.74 for $71,100, indicating recent insider selling activity.
- Stock and analyst context: ABEO trades around $5.31 with a $287.8M market cap and a 4.32 P/E; analysts on MarketBeat average a "Moderate Buy" rating with a $20 price target, though some firms have downgraded the stock.
Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) Director Mark Alvino sold 13,500 shares of Abeona Therapeutics stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $5.23, for a total transaction of $70,605.00. Following the sale, the director owned 48,752 shares of the company's stock, valued at approximately $254,972.96. The trade was a 21.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Mark Alvino also recently made the following trade(s):
- On Thursday, November 13th, Mark Alvino sold 15,000 shares of Abeona Therapeutics stock. The stock was sold at an average price of $4.74, for a total value of $71,100.00.
Abeona Therapeutics Stock Performance
Shares of ABEO stock opened at $5.31 on Thursday. The stock has a fifty day moving average price of $5.05 and a 200 day moving average price of $5.64. The stock has a market cap of $287.75 million, a PE ratio of 4.32 and a beta of 1.12. Abeona Therapeutics Inc. has a 1 year low of $3.93 and a 1 year high of $7.54. The company has a debt-to-equity ratio of 0.06, a quick ratio of 9.53 and a current ratio of 9.74.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. Sell-side analysts forecast that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
ABEO has been the subject of a number of research reports. Wall Street Zen cut shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, November 15th. Weiss Ratings downgraded Abeona Therapeutics from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, October 24th. Finally, HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Abeona Therapeutics in a report on Monday, October 13th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $20.00.
Check Out Our Latest Stock Report on ABEO
Hedge Funds Weigh In On Abeona Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. acquired a new stake in Abeona Therapeutics during the second quarter worth approximately $25,000. Legal & General Group Plc purchased a new position in shares of Abeona Therapeutics during the 2nd quarter worth $27,000. Russell Investments Group Ltd. acquired a new stake in shares of Abeona Therapeutics during the third quarter worth $37,000. Legato Capital Management LLC purchased a new stake in shares of Abeona Therapeutics in the third quarter valued at $57,000. Finally, SG Americas Securities LLC acquired a new position in Abeona Therapeutics in the fourth quarter valued at $57,000. Hedge funds and other institutional investors own 80.56% of the company's stock.
Abeona Therapeutics Company Profile
(
Get Free Report)
Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company's research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.
The company's lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
